Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: Results from a phase II study

Orazio Caffo, Lucia Fratino, Roberto Barbieri, Alessandra Perin, Thomas Martini, Teodoro Sava, Romana Segati, Emanuela Vaccher, Franco Bernardo Bassan, Antonello Veccia, Giovanni Pappagallo, Enzo Galligioni

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: Although there is no standard treatment after docetaxel failure in patients with castration-resistant prostate cancer (CRPC), second-line chemotherapy is increasingly required. Its mechanism of action and toxicity profile make pemetrexed suitable for testing in this setting. Methods and materials: Patients with docetaxel-resistant CRPC received pemetrexed 500 mg/m2 every 3 weeks for 6 courses. The usual premedication with vitamin supplementation and dexamethasone prophylaxis was regularly administered. The primary objective was to quantify the biochemical response rate. Results: The biochemical response rate was 10.5% (95% CI 1.3-33.1), with 2 patients showing a reduction in prostate specific antigen (PSA) of ≥50%. The null hypothesis that the PSA response rate would be less than 20% was therefore accepted, and patient accrual was stopped after the evaluation of the 19th patient. The 1-year overall survival rate was 61.5%, with a median survival of 14 months. A considerable proportion of the patients (36%) were withdrawn from the study because of hematologic and nonhematologic toxicity. Conclusions: Our experience with pemetrexed in CRPC patients appears discouraging in terms of activity and toxicity. No further studies of this drug should be performed in CRPC patients.

Original languageEnglish
Pages (from-to)180-186
Number of pages7
JournalUrologic Oncology: Seminars and Original Investigations
Volume31
Issue number2
DOIs
Publication statusPublished - Feb 2013

Fingerprint

docetaxel
Pemetrexed
Castration
Prostatic Neoplasms
Drug Therapy
Prostate-Specific Antigen
Premedication
Vitamins
Dexamethasone

Keywords

  • Castration-resistance
  • Pemetrexed
  • Prostate cancer
  • Second line chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure : Results from a phase II study. / Caffo, Orazio; Fratino, Lucia; Barbieri, Roberto; Perin, Alessandra; Martini, Thomas; Sava, Teodoro; Segati, Romana; Vaccher, Emanuela; Bernardo Bassan, Franco; Veccia, Antonello; Pappagallo, Giovanni; Galligioni, Enzo.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 31, No. 2, 02.2013, p. 180-186.

Research output: Contribution to journalArticle

Caffo, Orazio ; Fratino, Lucia ; Barbieri, Roberto ; Perin, Alessandra ; Martini, Thomas ; Sava, Teodoro ; Segati, Romana ; Vaccher, Emanuela ; Bernardo Bassan, Franco ; Veccia, Antonello ; Pappagallo, Giovanni ; Galligioni, Enzo. / Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure : Results from a phase II study. In: Urologic Oncology: Seminars and Original Investigations. 2013 ; Vol. 31, No. 2. pp. 180-186.
@article{00783024ace6416f873518c01e036dde,
title = "Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: Results from a phase II study",
abstract = "Objective: Although there is no standard treatment after docetaxel failure in patients with castration-resistant prostate cancer (CRPC), second-line chemotherapy is increasingly required. Its mechanism of action and toxicity profile make pemetrexed suitable for testing in this setting. Methods and materials: Patients with docetaxel-resistant CRPC received pemetrexed 500 mg/m2 every 3 weeks for 6 courses. The usual premedication with vitamin supplementation and dexamethasone prophylaxis was regularly administered. The primary objective was to quantify the biochemical response rate. Results: The biochemical response rate was 10.5{\%} (95{\%} CI 1.3-33.1), with 2 patients showing a reduction in prostate specific antigen (PSA) of ≥50{\%}. The null hypothesis that the PSA response rate would be less than 20{\%} was therefore accepted, and patient accrual was stopped after the evaluation of the 19th patient. The 1-year overall survival rate was 61.5{\%}, with a median survival of 14 months. A considerable proportion of the patients (36{\%}) were withdrawn from the study because of hematologic and nonhematologic toxicity. Conclusions: Our experience with pemetrexed in CRPC patients appears discouraging in terms of activity and toxicity. No further studies of this drug should be performed in CRPC patients.",
keywords = "Castration-resistance, Pemetrexed, Prostate cancer, Second line chemotherapy",
author = "Orazio Caffo and Lucia Fratino and Roberto Barbieri and Alessandra Perin and Thomas Martini and Teodoro Sava and Romana Segati and Emanuela Vaccher and {Bernardo Bassan}, Franco and Antonello Veccia and Giovanni Pappagallo and Enzo Galligioni",
year = "2013",
month = "2",
doi = "10.1016/j.urolonc.2010.11.012",
language = "English",
volume = "31",
pages = "180--186",
journal = "Urologic Oncology",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure

T2 - Results from a phase II study

AU - Caffo, Orazio

AU - Fratino, Lucia

AU - Barbieri, Roberto

AU - Perin, Alessandra

AU - Martini, Thomas

AU - Sava, Teodoro

AU - Segati, Romana

AU - Vaccher, Emanuela

AU - Bernardo Bassan, Franco

AU - Veccia, Antonello

AU - Pappagallo, Giovanni

AU - Galligioni, Enzo

PY - 2013/2

Y1 - 2013/2

N2 - Objective: Although there is no standard treatment after docetaxel failure in patients with castration-resistant prostate cancer (CRPC), second-line chemotherapy is increasingly required. Its mechanism of action and toxicity profile make pemetrexed suitable for testing in this setting. Methods and materials: Patients with docetaxel-resistant CRPC received pemetrexed 500 mg/m2 every 3 weeks for 6 courses. The usual premedication with vitamin supplementation and dexamethasone prophylaxis was regularly administered. The primary objective was to quantify the biochemical response rate. Results: The biochemical response rate was 10.5% (95% CI 1.3-33.1), with 2 patients showing a reduction in prostate specific antigen (PSA) of ≥50%. The null hypothesis that the PSA response rate would be less than 20% was therefore accepted, and patient accrual was stopped after the evaluation of the 19th patient. The 1-year overall survival rate was 61.5%, with a median survival of 14 months. A considerable proportion of the patients (36%) were withdrawn from the study because of hematologic and nonhematologic toxicity. Conclusions: Our experience with pemetrexed in CRPC patients appears discouraging in terms of activity and toxicity. No further studies of this drug should be performed in CRPC patients.

AB - Objective: Although there is no standard treatment after docetaxel failure in patients with castration-resistant prostate cancer (CRPC), second-line chemotherapy is increasingly required. Its mechanism of action and toxicity profile make pemetrexed suitable for testing in this setting. Methods and materials: Patients with docetaxel-resistant CRPC received pemetrexed 500 mg/m2 every 3 weeks for 6 courses. The usual premedication with vitamin supplementation and dexamethasone prophylaxis was regularly administered. The primary objective was to quantify the biochemical response rate. Results: The biochemical response rate was 10.5% (95% CI 1.3-33.1), with 2 patients showing a reduction in prostate specific antigen (PSA) of ≥50%. The null hypothesis that the PSA response rate would be less than 20% was therefore accepted, and patient accrual was stopped after the evaluation of the 19th patient. The 1-year overall survival rate was 61.5%, with a median survival of 14 months. A considerable proportion of the patients (36%) were withdrawn from the study because of hematologic and nonhematologic toxicity. Conclusions: Our experience with pemetrexed in CRPC patients appears discouraging in terms of activity and toxicity. No further studies of this drug should be performed in CRPC patients.

KW - Castration-resistance

KW - Pemetrexed

KW - Prostate cancer

KW - Second line chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=84875259992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875259992&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2010.11.012

DO - 10.1016/j.urolonc.2010.11.012

M3 - Article

C2 - 21803618

AN - SCOPUS:84875259992

VL - 31

SP - 180

EP - 186

JO - Urologic Oncology

JF - Urologic Oncology

SN - 1078-1439

IS - 2

ER -